STOCK TITAN

Immunome Inc. (IMNM) awards RSUs and stock options to its CMO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. granted Chief Medical Officer Robert Lechleider 54,000 RSUs and an employee stock option for 108,000 shares at a $22.01 exercise price on 2026-07-23. The RSUs vest 25% annually, while the options vest 25% on July 23, 2027 and monthly thereafter. After these awards he directly holds 69,805 common shares and 108,000 options.

Positive

  • None.

Negative

  • None.
Insider Lechleider Robert
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F2 108,000 $0.00 $0.00
Grant/Award Common Stock F1 54,000 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 108,000 shares (Direct); Common Stock — 69,805 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
  2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
RSUs granted 54000.0000 shares Restricted stock units granted on 2026-07-23
Options granted 108000.0000 shares Employee stock option granted on 2026-07-23
Option exercise price $22.0100 per share Exercise price for 108,000-share employee stock option
Option expiration date 2036-07-22 Expiration of employee stock option grant
Shares held after RSU grant 69805.0000 shares Direct common stock holdings following the RSU award
RSU annual vesting rate 25% RSUs vest 25% annually on each anniversary of grant
Initial option cliff vesting 25% on 2027-07-23 First tranche of options vests one year after grant
restricted stock units ("RSUs") financial
"underlying restricted stock units ("RSUs"). Each RSU represents the contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option financial
"security_title": "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
continuous service financial
"subject to the Reporting Person's continuous service through each such vesting date"
vest and settle financial
"RSUs will vest and settle into Common Stock annually on each anniversary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Immunome (IMNM) grant to CMO Robert Lechleider?

Immunome granted Robert Lechleider 54,000 restricted stock units and an employee stock option for 108,000 shares at a $22.01 exercise price. These awards were granted on July 23, 2026 and are reported as directly owned by him.

How do the RSUs granted to Immunome (IMNM) CMO vest?

The 54,000 RSUs vest and settle into common stock with 25% vesting annually on each anniversary of the July 23, 2026 grant date, subject to Robert Lechleider’s continuous service with Immunome through each applicable vesting date.

What is the vesting schedule for the 108,000 stock options reported by IMNM?

For the 108,000 stock options, 25% of the shares vest on July 23, 2027, and one-thirty-sixth of the remaining shares vest monthly thereafter. All vesting is conditioned on Robert Lechleider’s continuous service through each vesting date.

What is the exercise price and expiration date of the options in the IMNM Form 4?

The employee stock option has a $22.01 per-share exercise price and expires on July 22, 2036. It covers 108,000 shares of Immunome common stock, subject to the time-based vesting schedule described in the Form 4 footnotes.

How many Immunome (IMNM) common shares does Robert Lechleider hold after these grants?

Following the RSU grant, Robert Lechleider is reported as directly holding 69,805 shares of Immunome common stock. In addition, he holds an employee stock option covering 108,000 shares, which vests over time and has a $22.01 exercise price.

Were the IMNM insider awards to Robert Lechleider made under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked, and the filing does not state that these equity awards were granted pursuant to a 10b5-1 trading plan. They are reported simply as compensation-related acquisitions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lechleider Robert

(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026A54,000(1)A$069,805D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$22.0107/23/2026A108,000 (2)07/22/2036Common Stock108,000$0108,000D
Explanation of Responses:
1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
/s/ Sandra Stoneman, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)